GeneDx Holdings Corp. (WGS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
GeneDx Holdings Corp. (WGS) Q3 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sabrina Dunbar Katherine Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Bryan Dechairo - Chief Operating Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Daniel Brennan - TD Cowen, Research Division Mark Massaro - BTIG, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division David Westenberg - Piper Sandler & Co., Research Division William Bonello - Craig-Hallum Capital Group LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Keith Hinton - Prime Executions, Inc., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the GeneDx Third Quarter 2025 Earnings Conference Call.
GeneDx's Blueprint For The Next Healthcare Revolution
GeneDx Holdings is transforming into a global genetic software leader, leveraging its vast database and recent Fabric Genomics acquisition. WGS achieved strong Q2 results: 49% revenue growth, 71% gross margin, positive cash flow, and raised full-year guidance, signaling accelerating adoption. The AAP's new recommendations and NIH funding position WGS for significant market expansion, with insurance coverage supporting sustainable, recurring revenue.
How GeneDX CEO Katherine Stueland is using AI to save lives
She started her career helping launch breakthrough treatments for HIV and cancer. Today, Katherine Stueland is leading GeneDx — a genetic testing company using genomic insights to diagnose rare diseases faster and more accurately than ever before.
Will GENEDX HOLDINGS (WGS) Gain on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross?
GeneDx Holdings Corp. (WGS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, WGS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth
GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%. Revenue growth is driven by higher testing volumes, improved reimbursement rates, and a continued decline in denial rates. Momentum is building for 30%+ test volume growth in 2025, supported by testing for new indications, integration with Epic systems at hospitals, and Medicaid coverage.
GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Katherine A. Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Sabrina Dunbar - Corporate Participant Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Daniel Gregory Brennan - TD Cowen, Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Subhalaxmi T.
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Beat Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to a loss of $0.11 per share a year ago.
Why GENEDX HOLDINGS (WGS) Could Beat Earnings Estimates Again
GENEDX HOLDINGS (WGS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Exome and Genome Growth Boost WGS' Q2 Earnings?
GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.
GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
GENEDX HOLDINGS (WGS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
